ClinicalTrials.Veeva

Menu

Cologne Placenta Cohort (CPC)

S

Sarah Appel

Status

Active, not recruiting

Conditions

Obesity, Maternal
Gestational Diabetes Mellitus in Pregnancy

Treatments

Other: no intervention

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Aim of the study was to determine if signaling pathways in placentas of mothers affected by overweight/obesity or by gestational diabetes are altered compared to placentas of a control group (normal weight, no gestational diabetes). Moreover, maternal blood and umbilical cord blood were analysed.

Enrollment

247 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • singleton pregnancy
  • BMI before pregnancy >= 18
  • with & without gestational diabetes
  • c-section at gestational week 35+0 until 41+6

Exclusion criteria

  • multiple pregnancy
  • maternal serious internal disease
  • infections before pregnancy (e.g. HIV, hepatitis B)
  • pregnancy-associates diseases (e.g. gestoses, androgen insensitivity syndrome)

Trial design

247 participants in 6 patient groups

normal weight without gestational diabetes
Description:
BMI \< 25; normal glucose tolerance
Treatment:
Other: no intervention
normal weight with gestational diabetes
Description:
BMI \< 25; impaired oral glucose tolerance
Treatment:
Other: no intervention
overweight without gestational diabetes
Description:
BMI 25 - 29.9; normal glucose tolerance
Treatment:
Other: no intervention
overweight with gestational diabetes
Description:
BMI 25 - 29.9; impaired glucose tolerance
Treatment:
Other: no intervention
obese without gestational diabetes
Description:
BMI \>= 30; normal glucose tolerance
Treatment:
Other: no intervention
obese with gestational diabetes
Description:
BMI \>= 30; impaired glucose tolerance
Treatment:
Other: no intervention

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems